Observe Medical ASA: Mandatory notification of trades by primary insider

(Oslo, 20 July 2020) 
Notice of exercise of employee share options
In connection with the expiry date at 31 March 2020, postponed by the Board of Directors to no later than 30 September 2020, Kathrine Gamborg Andreassen, board member, have at 20 July 2020 given notice that she will exercise a total of 125,000 options in Observe Medical ASA in the next exercise window.

Employees at Navamedic ASA were granted options in Observe Medical ASA in connection with the demerger of Navamedic ASA’s Medtech division with transfer to Observe Medical ASA 31 October 2019. The weighted average option exercise price is NOK 3.12. Shares issued upon exercise are subject to a lock-up period of 24 months after exercise.

Mandatory notification of trade

Kathrine Gamborg Andreassen have at 20 July given notice that she will exercise 125,000 options in the Company, corresponding to 125,000 shares at the strike price of NOK 3.12 in the next exercise window decided by the Board of Directors.

Kathrine Gamborg Andreassen, has today, at 20 July 2020, through her wholly-owned company Soleglad Invest AS, sold 80,000 shares at an average price per share of NOK 16.12.

Following these transactions, Kathrine Gamborg Andreassen (incl. Soleglad Invest AS) will hold 586,668 shares and 0 options in the Company.

For further information, please contact:
Björn Larsson, CEO of Observe Medical
Mobile: +46 76 620 17 25
E-mail: bjorn.larsson@observemedical.com
About Observe Medical ASA:
Observe Medical develops and markets innovative hospital products that contribute to increased patient safety and a more efficient care system. The Company's headquarter is in Oslo and its operations are based out of Sweden. Observe Medical's initial product was Sippi®, the only digital urine meter with wireless data transfer to patient data management systems, which also prevents bacterial migration that can lead to urinary infections (Sippcoat®). Sippi® is CE marked and is currently being launched at selected hospitals in the Nordics and Germany.